September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Stephen Liu: Phase I Results of Obrixtamig in Small Cell Lung Cancer or Neuroendocrine Carcinomas
Jul 28, 2025, 13:27

Stephen Liu: Phase I Results of Obrixtamig in Small Cell Lung Cancer or Neuroendocrine Carcinomas

Stephen Liu, Medical Oncologist, Chief of Hematology and Oncology, Director of Thoracic Oncology, Head of Developmental Therapeutics, Associate Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a recent article by Martin Wermke et al published in Journal of Clinical Oncology:

“Phase I results of obrixtamig (DLL3-CD3 bispecific T-cell engager) (n=168 SCLC / neuroendocrine carcinoma).

Across doses/cohorts, RR 23%, DOR 8.5m (in large cell neuroendocrine, RR 70%). CRS in 57% (G3+ 3%).

Active challenger to tarlatamab.”

Title: Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas

Authors: Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel F. Sanmamed, Olatunji B. Alese, Cyrus M. Sayehli, Edurne Arriola, Jürgen Wolf, Liza C. Villaruz, Julia Bertulis, Matus Studeny, Mohamed Bouzaggou, Xiaoyan Fang, Daniel Morgensztern

Read the Full Article on Journal of Clinical Oncology

Stephen Liu: Phase I Results of Obrixtamig in Small Cell Lung Cancer or Neuroendocrine Carcinomas

More posts featuring Stephen Liu.